Tumor-specific targeting of a cell line with natural killer cell activity by asialoglycoprotein receptor gene transfer

Cancer Immunology, Immunotherapy

Volumn 50, Issue 10, 2001, Pages 549-556

  Schirrmann, T ^a   Pecher, G ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Asialoglycoprotein receptor; Gene transfer; Natural killer cells; Tumor targeting

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; CARBOHYDRATE; COMPLEMENTARY DNA; GALACTOSE; THOMSEN FRIEDENREICH ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; DNA MODIFICATION; DNA TRANSFECTION; DRUG ACTIVITY; DRUG MECHANISM; GENE TRANSFER; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NATURAL KILLER CELL; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL; TUMOR CELL DESTRUCTION;

ASIALOGLYCOPROTEIN RECEPTOR; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; DNA, COMPLEMENTARY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS; RECEPTORS, CELL SURFACE; TRANSFECTION;

EID: 0035667462     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-001-0236-4     Document Type: Article

References (47)

1. Differential role of mannose and glucose trimming in the ER degradation of asialoglycoprotein receptor subunits
2. NK cell activation: Distinct stimulatory pathways counterbalancing inhibitory signals
3. Immunoreactivity of Thomsen-Friedenreich (TF) antigen in human neoplasms: The importance of carrier-specific glycotope expression on MUC1
4. Inhibition of liver tumor cell colonization in two animal tumor models by lectin blocking with D-galactose or arabinogalactan
5. The H1 and H2 polypeptides associate to form the asialoglycoprotein receptor in human hepatoma cells
6. Cell therapy: Achievements and perspectives
7. Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin
8. Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation
9. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture
10. Prognostic significance of T antigen expression in patients with gastric carcinoma
11. Tumor cell surface beta 1-4-linked galactose binds to lectin(s) on microvascular endothelial cells and contributes to organ colonization
12. Tumor-specific T-bodies: Towards clinical application
13. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
14. Kat: A high-efficiency retroviral transduction system for primary human T lymphocytes
15. Endocytosis and recycling of subunit H1 of the asialoglycoprotein receptor is independent of oligomerization with H2
16. Oligomeric structure of the human asialoglycoprotein receptor: Nature and stoichiometry of mutual complexes containing H1 and H2 polypeptides assessed by fluorescence photobleaching recovery
17. Natural killer cell cytolytic activity is inhibited by NKG2-A and activated by NKG2-C
18. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile
19. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes
20. Liver lectin blocking with D-galactose to prevent hepatic metastases in colorectal carcinoma patients
21. A new monoclonal antibody (A78-G/A7) to the Thompson-Friedenreich pan-tumor antigen
22. Prevention of hepatic metastases by liver lectin blocking with D-galactose in stomach cancer patients. A prospectively randomized clinical trial
23. An alternatively spliced miniexon alters the subcellular fate of the human asialoglycoprotein receptor H2 subunit. Endoplasmic reticulum retention and degradation or cell surface expression
24. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma
25. Restoration of lytic function in a human natural killer cell line by gene transfection
26. Recognition of complex oligosaccharides by the multi-subunit asialoglycoprotein receptor
27. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor
28. Human NK-cell receptors
29. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells
30. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo
31. Successful liver metastasis model in mice with neuraminidase treated colon 26
32. Tumor progression in vivo: Increased soybean agglutinin lectin binding, N-acetylgalactosamine-specific lectin expression, and liver metastasis potential
33. + tumor cells by primary lymphocytes modified with chimeric T cell receptors
34. The two subunits of the human asialoglycoprotein receptor have different fates when expressed alone in fibroblasts
35. Inhibition of liver metastases from neuraminidase-treated colon 26 cells by an anti-Thomsen-Friedenreich-specific monoclonal antibody
36. Sequence of a second human asialoglycoprotein receptor: Conservation of two receptor genes during evolution
37. Cell adhesion inhibition by glycoliposomes: Effects of vesicle diameter and ligand density
38. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy
39. Membrane-bound versus secreted forms of human asialoglycoprotein receptor subunits. Role of a juxtamembrane pentapeptide
40. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes
41. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells
42. Prevention of hepatic metastases by liver lectin blocking with D-galactose in colon cancer patients. A prospectively randomized clinical trial
43. Natural killer cells and tumor therapy
44. An activating immunoreceptor complex formed by NKG2D and DAP10
45. Detection and quantification of soluble asialoglycoprotein receptor in human serum
46. Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience
47. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL2 receptor on a natural killer-like cell line (YT cells)